Literature DB >> 7710960

Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer.

Z F Zhang1, Z S Zeng, A S Sarkis, D S Klimstra, E Charytonowicz, D Pollack, J Vena, J Guillem, J R Marshall, C Cordon-Cardo.   

Abstract

To examine the hypothesis that colorectal carcinomas with and without TP53 mutations may be characterised by aetiological heterogeneity, we analysed a group of 107 patients with primary Dukes' C colorectal cancer seen at the Memorial Sloan-Kettering Cancer Center (MSKCC) from 1986 to 1990. We assessed p53 overexpression using the monoclonal antibody PAb 1801, and identified 42 (39%) patients displaying p53-positive phenotype, defined as > or = 25% of positive cells. Patients with two or more first-degree relatives with cancer had an odds ratio (OR) of 2.9 (95% CI 1.0-8.3) for p53 overexpression in comparison with those without a family history of cancer (trend test, P = 0.11). A possible association between body weight and p53 overexpression was observed. The ORs were 1.9 for the second quartile, 1.9 for the third quartile and 3.4 for the highest quartile in comparison with the lowest quartile (trend test, P = 0.06). No association between occupational physical activity, smoking, drinking, parity and p53 overexpression was identified. The results suggest that p53 overexpression may be related to genetic predisposition to colorectal cancer, and p53-positive and p53-negative colorectal cancers may be controlled by different aetiological pathways.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710960      PMCID: PMC2033726          DOI: 10.1038/bjc.1995.171

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  46 in total

Review 1.  Epidemiology of colorectal adenomatous polyps.

Authors:  A I Neugut; J S Jacobson; I De Vivo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Mar-Apr       Impact factor: 4.254

2.  Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study.

Authors:  B E Kreger; K M Anderson; A Schatzkin; G L Splansky
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

3.  Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.

Authors:  C H Spruck; W M Rideout; A F Olumi; P F Ohneseit; A S Yang; Y C Tsai; P W Nichols; T Horn; G G Hermann; K Steven
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

4.  Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer.

Authors:  D G Brachman; D Graves; E Vokes; M Beckett; D Haraf; A Montag; E Dunphy; R Mick; D Yandell; R R Weichselbaum
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

5.  p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand.

Authors:  M C Hollstein; C P Wild; F Bleicher; S Chutimataewin; C C Harris; P Srivatanakul; R Montesano
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

6.  Mutations in the P53 tumour suppressor gene in primary lung cancer in Japan.

Authors:  K Kondo; A Umemoto; S Akimoto; T Uyama; K Hayashi; Y Ohnishi; Y Monden
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

7.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners.

Authors:  K H Vähäkangas; J M Samet; R A Metcalf; J A Welsh; W P Bennett; D P Lane; C C Harris
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

8.  Quetelet's index and risk of colon cancer in college alumni.

Authors:  I M Lee; R S Paffenbarger
Journal:  J Natl Cancer Inst       Date:  1992-09-02       Impact factor: 13.506

9.  p53 mutations in human lung tumors.

Authors:  C W Miller; K Simon; A Aslo; K Kok; J Yokota; C H Buys; M Terada; H P Koeffler
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

Review 10.  Apoptosis (the 1992 Frank Rose Memorial Lecture).

Authors:  A H Wyllie
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more
  6 in total

1.  No major difference in K-ras and p53 abnormalities in sporadic and hereditary nonpolyposis colorectal adenomas.

Authors:  D W Voskuil; E Kampman; W van Geloof; M Grubben; F Kok; G van Muijen; F Nagengast; H Vasen; P van't Veer
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

2.  Adiposity is associated with p53 gene mutations in breast cancer.

Authors:  Heather M Ochs-Balcom; Catalin Marian; Jing Nie; Theodore M Brasky; David S Goerlitz; Maurizio Trevisan; Stephen B Edge; Janet Winston; Deborah L Berry; Bhaskar V Kallakury; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2015-09-12       Impact factor: 4.872

3.  Association of prediagnostic physical activity with survival following breast cancer diagnosis: influence of TP53 mutation status.

Authors:  Meng-Hua Tao; Pierre Hainaut; Catalin Marian; Jing Nie; Christine Ambrosone; Stephen B Edge; Maurizio Trevisan; Joan Dorn; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2013-09-26       Impact factor: 2.506

4.  Interaction of molecular markers and physical activity on mortality in patients with colon cancer.

Authors:  Jeffrey A Meyerhardt; Shuji Ogino; Gregory J Kirkner; Andrew T Chan; Brian Wolpin; Kimmie Ng; Katsuhiko Nosho; Kaori Shima; Edward L Giovannucci; Massimo Loda; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

5.  Influence of anthropometric factors on tumour biological characteristics of colorectal cancer in men and women: a cohort study.

Authors:  Jenny Brändstedt; Sakarias Wangefjord; Signe Borgquist; Björn Nodin; Jakob Eberhard; Jonas Manjer; Karin Jirström
Journal:  J Transl Med       Date:  2013-11-21       Impact factor: 5.531

6.  The relationship between smoking exposure and p53 overexpression in colorectal cancer.

Authors:  A N Freedman; A M Michalek; J R Marshall; C J Mettlin; N J Petrelli; Z F Zhang; J D Black; S Satchidanand; J E Asirwatham
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.